Advances in Eicosanoid Research

1. Front Matter

   Pages I-XII

   PDF

2. The Mechanism of Action of Anti-Inflammatory Drugs

   • J. R. Vane

   Pages 1-23

3. Human Group-V Phospholipase-A2 Expression in Pichia pastoris and Its Role in Eicosanoid Generation

   • L. J. Lefkowitz, H. Shinohara, E. A. Dennis

   Pages 25-52

4. Fatty-Acid Substrate Interactions with Cyclo-oxygenases

   • W. L. Smith, C. J. Rieke, E. D. Thuresson, A. M. Mulichak, R. M. Garavito

   Pages 53-64

5. Structure, Function and Inhibition of Cyclo-oxygenases

   • L. J. Marnett

   Pages 65-83

6. Leukotriene-A4 Hydrolase: Probing the Active Sites and Catalytic Mechanisms by Site-Directed Mutagenesis

   • J. Z. Haeggström, A. Wetterholm

   Pages 85-96

7. The Regulation of Cyclooxygenase-1 and -2 in Knockout Cells and Cyclooxygenase and Fever in Knockout Mice

   • L. R. Ballou

   Pages 97-124

8. Leukotriene-B4 Receptor and Signal Transduction

   • T. Shimizu, T. Yokomizo, T. Izumi

   Pages 125-141

9. Lipoxins, Aspirin-Triggered 15-epi-Lipoxin Stable Analogs and Their Receptors in Anti-Inflammation: A Window for Therapeutic Opportunity

   • C. N. Serhan, B. D. Levy, C. B. Clish, K. Gronert, N. Chiang

   Pages 143-185

10. Lipoxin-Stable Analogs: Potential Therapeutic Downregulators of Intestinal Inflammation

    • A. T. Gewirtz, J. L. Madara

    Pages 187-199

11. The Role of Eicosanoids in Tumor Growth and Metastasis

    • D. Nie, K. Tang, K. Szekeres, M. Trikha, K. V. Honn

    Pages 201-217

12. Back Matter

    Pages 219-225

    PDF

Over the last few years, we have witnessed tremendous progress in the field of eicosanoids and their therapeutic applications. Receptor an­ tagonists for leukotrienes have been tested as anti-inflammatories and are on the market as a treatment for asthma. Receptor agonists for pro­ stacyclin are being tested for the treatment of peripheral vascular dis­ ease, and selective inhibitors of cyclooxygenase type II were just ap­ proved for the treatment of rheumatoid arthritis. All these developments are the culmination of many years and man-hours of careful research. The field has now entered an upswing that will result in novel thera­ peutic applications within the next 10 years. New molecules and me­ diators have been identified, new enzymes and pathways elucidated and new therapeutic approaches have emerged. The concept of ei­ cosanoids as "pro-inflammatory" molecules is being challenged, and their role as regulators is increasingly recognized. In fact, some of these molecules may be important endogenous anti-inflammatory agents.

• Anti-Inflammatory Drugs
• Asthma
• Eicosanoide
• Termination
• cyclooxygenase
• enzymes
• metabolism
• signal transduction

• Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, USA

  C. N. Serhan

• Dept. of Immunology, Berlex Biosciences, Richmond, USA

  H. D. Perez

Policies and ethics